Chengdu Kanghong Pharmaceutical Group Co Ltd

Chengdu Kanghong Pharmaceutical Group Co Ltd maintains a strong liquidity position, with a current ratio of 11.77, indicating a significant buffer of current assets over current liabilities. The company's liquidity_fpt score is high, supported by a robust cash and equivalents balance of CNY 51.64 million and a free cash flow of CNY 568.49 million. The company's debt structure is minimal, with long-term debt amounting to only CNY 3.51 million, and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. In terms of profitability, the company's return on equity (ROE) of 12.51% and return on assets (ROA) of 11.72% are strong, outperforming the typical benchmarks for the pharmaceutical industry. The net income of CNY 1.16 billion and operating income of CNY 1.38 billion reflect a healthy margin structure, with a gross profit of CNY 4.12 billion on total revenue of CNY 4.59 billion. The company's revenue is primarily concentrated in its domestic operations, with no disclosed international segments. This concentration may expose the company to regulatory and economic risks specific to China. The valuation_snapshot does not provide segment-specific revenue breakdowns, but the lack of international diversification is evident from the absence of foreign revenue disclosures. Looking ahead, the company is projected to maintain a stable growth trajectory, with analysts forecasting a mean EPS estimate of CNY 1.58 for the current fiscal year, compared to the last actual EPS of CNY 1.26. The mean recommendation from analysts is a "strong buy," with two strong-buy ratings and no sell or strong-sell ratings, indicating a positive outlook. The risk assessment for the company is favorable, with low liquidity and dilution risks. No immediate filing-based liquidity or dilution flags were detected, and the company's capital structure remains stable with no near-term dilution pressures. The dilution_potential_basic is low, and no adjustments were applied in the custom_valuations. Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's financial snapshot remains consistent with its historical performance, and there are no disclosed events that would significantly alter its current trajectory.